SCHEMBL985968

SCHEMBL985968

N#Cc1c[nH]c2ccc(C3(Cc4ccccn4)CCN(Cc4ccccc4)C3)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.54
CYP2D6 P10635 2/20 0.54
SLC6A2 P23975 2/20 0.54
SLC6A3 Q01959 2/20 0.54
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
DRD4 P21917 4/20 0.36
DRD3 P35462 4/20 0.36
DRD2 P14416 3/20 0.36
IMPDH2 P12268 1/20 0.36
OPRM1 P35372 2/20 0.35
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
ABCB1 P08183 1/20 0.34
ABCC1 P33527 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
KDM4E B2RXH2 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL983186 0.89 SLC6A4 (0.67) SLC6A4CYP2D6SLC6A2SLC6A3DRD4
SCHEMBL983459 0.84 ACHE (0.40) SLC6A4CYP2D6SLC6A2SLC6A3LMNA
SCHEMBL980402 0.82 SLC6A2 (0.63) SLC6A4CYP2D6SLC6A2SLC6A3LMNA
SCHEMBL982219 0.80 SLC6A2 (0.73) SLC6A4CYP2D6SLC6A2SLC6A3IMPDH2
SCHEMBL982085 0.72 SLC6A2 (0.52) SLC6A4CYP2D6SLC6A2SLC6A3LMNA
SCHEMBL982660 0.72 CYP2D6 (0.44) SLC6A4CYP2D6SLC6A2SLC6A3LMNA
SCHEMBL986649 0.70 SLC6A4 (1.00) SLC6A4CYP2D6SLC6A2SLC6A3IMPDH2
SCHEMBL984260 0.69 SLC6A2 (0.63) SLC6A4CYP2D6SLC6A2SLC6A3KDM4E
SCHEMBL980094 0.66 CYP2D6 (0.60) SLC6A4CYP2D6SLC6A2SLC6A3LMNA
SCHEMBL984635 0.65 CYP2D6 (0.62) SLC6A4CYP2D6SLC6A2SLC6A3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 SLC6A4 8/4885CYP2D6 97/4885SLC6A2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.